New Delhi: The Indian Pharmacopoeia Commission (IPC), in its latest Drug Safety Alert, has flagged a safety signal indicating that the antihypertensive drug Metoprolol may be associated with hyperkalemia, a condition characterised by an abnormally high level of potassium in the blood. This follows an analysis of adverse drug reaction (ADR) reports available in the Pharmacovigilance Programme of India (PvPI) database, which identified hyperkalemia as a suspected adverse reaction associated with Metoprolol. According to the IPC safety alert, it is also used as an adjunct in the treatment of hyperthyroidism. As per the issued Drug Safety Alert, the suspected drug and its associated ADR are as follows:S. No. Suspected Drug Indication(s) Adverse Drug Reaction 1 Metoprolol Antihypertensive agent- Indicated in the treatment of essential hypertension and angina pectoris.